Oncological outcome and prognostic factors in the therapy of soft tissue sarcoma of the extremities

Ipach Ingmar,1 Wingert Tobias,1 Kunze Beate,1 Kluba Torsten1,2
1Department of Orthopaedic Surgery, University of Tuebingen; 2Comprehensive Cancer Center Tübingen, University of Tuebingen, Germany

Abstract

Uniform conclusions about therapeutic concepts and survival time of bone and soft tissue sarcoma patients are difficult due to the heterogeneity of histological subtypes as well as the different responses to neoadjuvant therapy. The subject of this retrospective study was the analysis of tumour free survival, risk and prognostic factors of sarcoma patients treated by limb sparing techniques or amputation. We included 118 patients with soft tissue sarcoma of the extremities treated primarily or secondarily at our institution between 1990 and 2008 with a minimum follow-up of 12 months. Data about the tumour free survival time, operative techniques and potential prognostic factors were analysed. The tumour-specific and overall survival were significantly influenced by two factors: the grading and distant metastases present at time of diagnosis. Optimal multimodal therapeutic concepts at a specialized Cancer Center decreased the risk of local recurrence. The importance of optimal preoperative and surgical course concerning the oncological long term outcome was investigated. The decrease in local recurrence as a result of multimodal therapeutic concepts at a specialized Cancer Center was confirmed. To evaluate the individual prognosis of a patient, multiple factors have to be considered. Factors for a poor prognosis are primary metastasis, high-grade tumours and several histological entities (e.g. synovial sarcoma, not other specified).

Introduction

Bone and soft tissue sarcoma occur with a rare incidence of 1-2% of all malignancies. Because of advancements in multimodal therapy concepts, the number of limb sparing operations as well as the overall survival time have increased in recent years.

Due to the heterogeneity of histological subtypes as well as the different response to neoadjuvant therapy, uniform conclusions about therapeutic concepts and survival time are difficult.

A major determinant of the outcome is R0-resection with adequate margins, as a microscopically positive R1-resection correlates with an increased risk of local recurrence. In cases with no adequate margins, a re-resection to achieve negative margins should be performed as it directly correlates with improved local control, metastasis-free survival and disease-specific overall survival.

Some promising outcomes in patients with high-risk sarcomas (large, G1/GII, narrow margin, high-risk histological subtypes) were achieved by a preoperative combination of radiotherapy and chemotherapy (neoadjuvant) followed by an adequate R0-resection. This kind of therapy may also lead to a decrease in tumour-volume and less radical surgery could be performed.

The survival-rate for patients with metastatic disease (stage III according to Enneking/ IV UICC/AJCC) is poor. The most common site of metastases after primary treatment of an extremity sarcoma is the lung and they usually occur within 2-3 years after surgical treatment. For exclusion of lung metastases, a computed tomography (CT) of the chest should be performed every six months after tumour resection.

Patients with widely disseminated metastatic disease are best treated with palliative chemotherapy, although their survival rate is poor.

The subject of this retrospective study was the analysis of tumour free survival, risk and prognostic factors of patients treated by limb sparing techniques or amputation.

Materials and Methods

We reviewed the medical records of all patients who presented with the diagnosis of a soft tissue sarcoma at our hospital in the period between 1990 and 2008. Criteria for the inclusion in this study were the diagnosis of a soft tissue sarcoma confirmed by pathology, meaningful clinical information and histological material and achievement of a minimum postoperative follow-up of 12 months. To complete the medical records, we contacted the local family doctor.

We analyzed the data with regard to tumour free survival time, operative techniques and potential prognostic factors (e.g. TNM staging, grading, histological entity, resection status). Because of the long observation period (1990-2008) and because most of the tumours originated in the axial skeleton, the Enneking classification system of orthopaedic oncology was used. It had been proved to be reliable, reproducible and of prognostic importance.

Statistical analysis

Categorical variables are presented as frequencies and percentages, and continuous variables as means and standard deviations. The Kaplan-Meier method was used to estimate tumor-specific and overall survival, with the log-rank test to determine significance. Hazard ratios and 95% confidence intervals for mortality were estimated with the use of Cox proportional-hazards regression models.

All reported P values are two-sided, with a significance level of 0.05 and have not been adjusted for multiple testing. All analyses were performed with the use of SPSS software.

Results

General data

One-hundred eighteen patients were included with a soft tissue sarcoma treated at our institution during the observation period and had a minimum follow-up of 12 months. 60 were female and 58 were male. The average age of patients at the time of diagnosis was 54.8±17 years. The average time between symptom onset and diagnosis was 10.4±17.9
months, the time between diagnosis and surgery was 32.1±29.3 days. In 58 patients (49.2%) the sarcoma occurred in the thigh, in the upper arm in 14 patients (11.9%) and the lower leg with 12 patients (10.2%). Localisations of the different kind of tumours are shown in Figure 1.

The most common imaging technique for the assessment of the primary tumour at diagnosis was the magnetic resonance imaging (MRI). It was performed in 87.2% of all patients. To determine the degree of spread of the tumour, preferred imaging procedures were CT of the chest (71.6%) and abdomen (37.6%), X-ray of the chest (57.8%) and bone scintigraphy (63.1%).

Liposarcoma and NOS (not other specified) were the most common histological entities, occurring in 49.15% of patients (Figure 2).

A stage IIb according to Enneking was observed in 54% of the cases. The grading was ≥GI in 78% of the tumours.

Stage T2b was most frequently diagnosed (69.0%). The regional lymph nodes were affected in only 3.5% of all study patients at the time of initial diagnosis. 6.8% of patients had distant metastases at first presentation.

The mean follow-up after surgery was 58 months.

At the end of the observation period, the patient’s status was re-evaluated. At this time no clinical or radiological evidence of disease was seen in 50.85% of patients. Every fourth patient died as a result of the sarcoma and its consequences. No data could be collected in every tenth case. Six percent of patients died of another disease unrelated to the tumour. Almost seven percent were alive at the end of the observation period with evidence of the tumour (Figure 3).

**Biopsy**

One third of patients (34.7%) were not assigned to our department until external pre-treatment. Patients treated primarily at our institution received a diagnostic biopsy in 98.2% (81.7% open biopsy). Patients who underwent primary surgery at an external hospital underwent a biopsy prior to the resection in only 8.1% of the cases. No significant differences concerning the grading or the tumour status according to Enneking in the subgroups of patients (external operation vs. surgery at a cancer center) were seen.

**Status of resection and local relapse**

Despite initial R0-resection in 97% of the cases (82.4% of patients treated at our institution, 18.4% of patients treated externally), local relapse within the observation period was seen in 21.7% of the patients. The risk of local recurrence was significantly less in the group

---

**Figure 1. Locations of the analysed soft tissue sarcomas.**

**Figure 2. Histological entities (n=118).**

**Figure 3. Status of disease at the end of the observation period (n=118). AWD, alive with disease; DOC, death from other causes; DOD, death from disease; NED, no evidence of disease.**
of patients treated at our institution from the beginning: 9.1% vs 17.2% in the first year, 12.5% vs 32.5% after 3 years and 21.2% vs 45.7% after 5 years (P=0.013) (Figure 4).

The risk of local recurrence increased with the T stage (P=0.056) and significantly with the tumour stage according to Enneking: stage I 8.7%; 8.7%; 17%; stage II 9.2%; 18.7%; 29.1%; stage III 25%; 50%; 55% one/three/five years after surgery (P=0.04).

A higher risk of local recurrence was also seen in patients without adjuvant therapy (P=0.089) and patients without initial R0 resection (despite local re-resection) (P=0.179).

**Distant metastases and overall survival**

During the observation period, 45 of 114 patients (39.5%) developed distant metastases. The lung was the mainly affected organ (34.7%).

Analysis of survival, depending on the grading, showed a statistically significant difference: one year after diagnosis all patients with low grade sarcoma (G1) were still alive (90.5% after three, 82.3% after five years). In the high grade sarcoma group (G>1) 95.3% of study patients were still alive one year after surgery, (83% after three, 48.8% after five years) (α=0.035). The median survival for high grade sarcomas was 60 months (Figure 5).

The median survival diminished significantly with primary metastases at first presentation (median survival 20 months).

Regarding the tumour-specific survival depending on the tumour stage according to Enneking, a 5-year survival of 86.1%, 53.7% and 33.3% in stage I, II, and III was seen (P<0.05). Concerning the T stage, 71.8% and 55.2% of patients after T1 or T2 sarcomas survived after 5 years (P=0.172).

**Multivariant analysis**

Patients pre-treated at an external hospital had, compared with those who underwent primary surgery at our institution, twice the risk of local tumour recurrence (P=0.003). Similarly, the risk for patients who received no adjuvant therapy (radio- or chemotherapy) was doubled (P=0.082). Another factor influencing the risk of relapse was the tumour size. The risk of local relapse between T2- and T1-sarcomas was 4.5-fold higher (P=0.046). Regarding the stage according to Enneking (III vs II and II vs I) a three-fold increased risk of local recurrence was associated with the higher tumour stage (P=0.029) (Table 1).

The tumour-specific and overall survival were significantly influenced by two factors: the grading and present distant metastases at time of diagnosis (Table 2).
We were able to demonstrate different factors which influence the tumour-specific survival such as clinical staging and grading. Patients with metastatic disease at initial diagnosis had a poor prognosis with a five year survival of about 33% which is also consistent with the published data of previous studies.11,12,18

According to the literature, important prognostic factors for overall survival, in addition to the histopathological grading, include the size of the primary tumour. The larger the tumour (T stage), the worse the respective survival rates.19-21 Positive surgical resection margins and certain histological subtypes not only increase the rate of local recurrence, but also affect overall survival.20,22,24 Another prognostic factor for overall survival is the location of the tumour. Superior soft tissue sarcomas have a significantly better prognosis than subfascial located tumours.20,22 We often see a significant delay in the time between symptom onset and diagnosis for deep located lesions. Because of the significantly higher incidence of benign compared to malignant neoplasms, the cause of such a lesion is often trivialized.24

An association between the development of local recurrence and a significantly poorer survival was shown in several studies.17,20,21

We note several limitations of the present study. We used the clinical staging described by Enneking. Today the classification system by the UICC is much more common. The UICC/AJCC was established in 2010 in its final version. During the observation period the Enneking staging was more commonly used. However, the Enneking classification is still reliable, reproducible and of prognostic importance and is used by many orthopaedic surgeons, as it includes the local extent of the tumour, which may be a prognostic factor.15

There are positive aspects in both classification systems and we agree with the statement of Jawad et al.15 that a combination of both classification systems might be of some benefit.

Finally, the clinical use of prognostic factors has been very helpful. However, the use of prognostic factors in individual cases is very difficult because of the biological behaviour and the several histological subtypes of soft tissue sarcomas. All patients with a possible STS should be assigned to a centre which is familiar with these kinds of tumours to optimize their outcome.

References

1. Mendenhall WM, Indelicato DJ, Scarborough MT, et al. The management of adult soft tissue sarcomas. Am J Clin Oncol 2009;32:436-42.
2. Heslin MJ, Woodruff J, Brennan MF. Prognostic significance of a positive microscopic margin in high-risk extremity soft tissue sarcoma: implications for management. J Clin Oncol 1996;14:473-8.
3. Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol 2003;21:2719-25.
4. McKee, Lui DF, Brooks JJ, et al. The prognostic significance of margin width for extremity and trunk sarcoma. J Surg Oncol 2004;85:68-76.
5. Stojadinovic A, Leung DH, Allen P, et al. Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables. J Clin Oncol 2002;20:2719-25.
6. Zagars GK, Ballo MT, Pisters PW, et al. Surgical margins and resection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer 2003;97:2544-53.
7. Fiore M, Casali PG, Miceli R, et al. Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity. Ann Surg Oncol 2006;13:110-7.
8. DeLaney TF, Spiro J, Suit HD, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2003;56:1117-27.
9. Corman JM, Huang X, Xing Y, et al. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol 2004;22:4567-74.
10. Pisters PW, Patel SR, Prieto VG, et al. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J Clin Oncol 2004;22:3375-80.
11. Putnam JB Jr, Roth JA, Wesley MN, et al. Analysis of prognostic factors in patients undergoing resection of pulmonary metastases from soft tissue sarcomas. J Thorac Cardiovasc Surg 1984;87:260-8.
12. Jablons D, Steinberg SM, Roth JA, et al. Metastasectomy for soft tissue sarcoma. Further evidence for efficacy and prognostic indicators. J Thorac Cardiovasc Surg 1989;97:695-705.
13. Kane JM. Surveillance strategies for patients following surgical resection of soft tissue sarcomas. J Thorac Cardiovasc Surg 1989;97:695-705.
14. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980;153:106-20.
15. Jawad UM, Scully SP. Classifications in brief: Enneking classification: benign and malignant tumors of the musculoskeletal system. Clin Orthop Relat Res 2010;468:2000-2.
16. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma. Vol 1. 2011. Available from: www.nccn.org. Accessed: May 2011.
17. Van Glabbeke M, van Oosterom AT.

---

Table 1. Prognostic factors for local relapse.

|                        | Hazard ratio | Confidence interval: lower level | Confidence interval: upper level | P-value |
|------------------------|--------------|----------------------------------|----------------------------------|---------|
| Enneking Stage: I a/b  | 2.992        | 1.119                            | 7.997                            | P=0.029 |
| II a/b; III a/b        | 4.495        | 1.029                            | 19.627                           | P=0.046 |
| Size: T1, T2          | 1.955        | 1.256                            | 3.043                            | P=0.003 |
| Surgery our institution | 2.073        | 0.912                            | 4.712                            | P=0.082 |

Table 2. Prognostic factors for tumour specific survival.

|                        | Hazard ratio | Confidence interval: lower level | Confidence interval: upper level | P-value |
|------------------------|--------------|----------------------------------|----------------------------------|---------|
| Grading Low grade (G1) | 3.415        | 1.035                            | 11.268                           | P=0.044 |
| High grade (G>2)      | 6.107        | 2.341                            | 15.929                           | P<0.0001|

We refer to the literature for a detailed discussion on the significance of these factors and their impact on survival.
Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens a European Organization for research and treatment of cancer soft tissue and bone sarcoma group study. J Clin Oncol 1999;17:150-7.

18. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003;CD003293.

19. Peabody TD, Monson D, Montag A, et al. A comparison of the prognoses for deep and subcutaneous sarcomas of the extremities. J Bone Joint Surg Am 1994;76: 167-73.

20. Pisters PW, Leung DH, Woodruff J, et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996;14:1679-89.

21. Stojadinovic A, Leung DH, Allen P, et al. Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables. J Clin Oncol 2002;20):4344-52.

22. Lewis JJ, Leugg D, Casper ES, et al. Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. Arch Surg 1999;134:190-4.

23. Canter RJ, Beal S, Borys D, et al. Interaction of histologic subtype and histologic grade in predicting survival for soft tissue sarcomas. J Am Coll Surg 2010;210: 191-8.

24. Canter RJ. Why do patients with low-grade soft tissue sarcoma die? Ann Surg Oncol 2008;15:3550-60.

25. Tsujimoto M, Aozasa K, Ueda T, et al. Multivariate analysis for histologic prognostic factors in soft tissue sarcomas. Cancer 1988;62:994-8.

26. Lawrence W Jr, Donegan WL, Natarjan N, et al. Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg 1987;205:349-59.

27. Eilber FC, Rosen G, Nelson SD, et al. High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg 2003;237:218-26.

28. Trovik CS, Bauer HC, Alvegard TA, et al. Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. Eur J Cancer 2000;36:710-6.